Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

NCT01158105 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft-versus-host Disease

Interventions

DRUG: Bortezomib

Sponsor

Baylor Research Institute

Collaborators

[object Object]